RGC
RGC
KYG7487R1002
Regencell Bioscience Holdings L
Loading chart...
Pure Price Volatility Risk (Market Swings)

The business itself is financially solid (Financial Health 75/100, minimal insolvency risk). The high overall score (7/7) is driven primarily by extreme stock price swings (±276.6% p.a.) and steep historical drawdowns.

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors.

Beta (Market Relation)
-
Defensive
Volatility (5Y p.a.)
276.6% p.a.
5-Year Horizon
Max Drawdown (5Y)
-93.9%
5-Year Horizon
Sharpe Ratio
0.25
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

Volatility Expansion (3Y > 5Y) High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — -60.7%
3 Years 349.8% -93.9% 0.45 +161.3%
5 Years 276.6% -93.9% 0.25 +72.3%
10 Years — — — —

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Exemplary balance sheet strength: Very solid ratio of equity to debt.
Elevated Short-Term Volatility: 3Y volatility (349.8%) is noticeably higher than the 5Y average (276.6%).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (276.6% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -93.9% in the extended horizon.

Corporate Governance & ISS Scores

Shareholder rights, board structure and audit safety (Scale 1 = Low Risk, 10 = High Risk)
Overall Governance Risk
-
Audit Risk
-
Board Risk
-
Short Ratio
4.30
ende